Clinical Trial

The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients With Coronary ISR

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to evaluate the safety and effectiveness of Genoss® SCB by comparing in-segment late lumen loss (LLL) to the control group (SeQuent® Please NEO) at 6 months in patients with coronary stent-in-stent restenosis (ISR) with a reference vessel diameter of 2.0-4.0 mm.
Trial Details
NCT Number NCT07159087
Lead Sponsor Genoss Co., Ltd.
Collaborators: Synex Consulting Ltd
Conditions Coronary Arterial Disease (CAD)
Enrollment 94 participants
Start Date 2025-02-19
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08